$BIIB $349.16? You have to be crazy to think it will stay this low for long. $BIIB WILL CLOSE bright GREEN FRIDAY.
$BIIB 4 STRAIGHT RED DAYS. Today was an OVERREACTION, OVERSOLD. AVERAGE price target among 33 analysts is $420! Highest price target $647!
Irrational markets. A SECOND Biogen drug for Alzheimer gets a thumbs up from the FDA, & it sells off!??? It was the WORST performing stock in the DOW 2 days in a row. LLY’s anti amyloid drug also got a nod from the FDA today, reiterating efficacy of the data against amyloid! So this should be GREAT NEWS for $BIIB as well.
$BIIB Today proves the FDA was right in approving the alzheimers drug a few weeks ago. $LLY using the same anti amyloid drug reiterating the efficacy of the data against amyloid! $LLY WAS GREAT NEWS for $BIIB & not bad. #HEDGEFUNDS LOADING HEAVY today. I guarantee it
$BIIB What the studies show is putting out the fire after the forest has burned doesn’t return it to its original splendor.
Removing the fire as soon as it’s ignited can save the forest!
Getting the plaques out as soon as the show up has been proven to slow the decline- to what extent- that’s why the approval was so needed so we can answer that- and that’s why it was a broad approval with no restrictions.
$BIIB is A 1000 stock!
$BIIB: Cowen Upgrades To Outperform PT $450
Atlantic Equities Upgrades to Neutral - PT $415
Citigroup Upgrades to Neutral PT $440
Oppenheimer Raises Target Price To $450 From $325
Morgan Stanley Raises Target Price To $455 From $343
Jeffries PT $500
$LLY drug is NOT EVEN APPROVED! $LLY is green from news of a drug using an approach "similar" to $BIIB with worse side effects that's in phase TWO? & $BIIB crashes from this?! If anything it AFFIRMS $BIIB drug works b/c $LLY using the same method.
$LLY is STEPS BEHIND $BIIB they're using a similar approach of anti-body. It would be 1-2 years before $LLY drug can be approved. At this time, $BIIB already occupies the market, just like Viagra. SO WHY IS $LLY UP $16 BILLION IN marketcap today & $BIIB down?
$BIIB "has the potential to generate (at least) $10 billion in peak sales" and a successful launch "has the potential to completely change the profile of the company," Guggenheim analyst Yatin Suneja said. $LLY news was great but TODAY, $BIIB DRUG IS THE ONLY ONE IN TOWN. PERIOD
REALITY WILL SET IN tomorrow, smart money will soak up all these gifts. More than 6 million Americans suffer from Alzheimer's, the sixth-leading cause of death in the U.S., & by some industry estimates the number of sufferers could double in the decades ahead. $BIIB CURRENTLY A MONOPOLY in the treatment of Alzheimer.
Aduhelm could reach $10 billion peak sales, Bernstein analysts said. Meanwhile, Cantor Fitzgerald analysts wrote that $BIIB "is now set up for one of the biggest drug launches in biopharma history." Predicted peak sales of roughly $8.2 billion in 2028.
SEE U AT $500+?????????
